Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 2/20 | 0.49 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.47 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27687287 | 0.98 | LMNA (0.60) | LMNAKDRRAPGEF4MAPTALDH1A1 | |
| SCHEMBL11376479 | 0.85 | ABL1 (0.55) | LMNAKDRRAPGEF4MAPTALDH1A1 | |
| SCHEMBL13969411 | 0.83 | RAF1 (0.51) | LMNAKDRMEN1KMT2A | |
| SCHEMBL10689579 | 0.81 | LMNA (0.53) | LMNAKDRRAPGEF4MAPTALDH1A1 | |
| SCHEMBL12883455 | 0.80 | KDR (0.57) | LMNAKDRRAPGEF4MAPTALDH1A1 | |
| SCHEMBL3269568 | 0.80 | AR (0.50) | LMNAARGRM4IDO1 | |
| SCHEMBL1800248 | 0.80 | AR (0.50) | LMNAKDRRAPGEF4MAPTALDH1A1 | |
| SCHEMBL6153068 | 0.79 | KDR (0.61) | LMNAKDRRAPGEF4MAPTALDH1A1 | |
| SCHEMBL9558300 | 0.79 | KDR (0.49) | LMNAKDRRAPGEF4MAPTALDH1A1 | |
| SCHEMBL9558305 | 0.79 | KDR (0.49) | LMNAKDRRAPGEF4MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20170226051-A1 | 10-SUBSTITUTED COLCHICINOIDS AS POTENT ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-08-10 | — | — | US | disclosed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-7951950-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-7846931-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| CN-101146776-A | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARM INC (US) | 2008-03-19 | — | — | CN | disclosed |
| EP-1861372-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-05 | — | — | EP | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
| US-20060241109-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
| WO-2006091674-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | LMNA 1345/4885KDR 145/4885RAPGEF4 1183/4885 |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | LMNA 4759/4885KDR 222/4885RAPGEF4 677/4885 |
| US-20170226051-A1 | 10-SUBSTITUTED COLCHICINOIDS AS POTENT ANTICANCER AGENTS | HCCS, CDC20, TOP2B | LMNA 1823/4885KDR 3413/4885RAPGEF4 3996/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | LMNA 3037/4885KDR 719/4885RAPGEF4 477/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | LMNA 1466/4885KDR 127/4885RAPGEF4 1156/4885 |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | LMNA 3852/4885KDR 1658/4885RAPGEF4 3286/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | LMNA 4759/4885KDR 222/4885RAPGEF4 677/4885 |
| US-20060241109-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGER2, PTGDR2, PTGER1 | LMNA 4123/4885KDR 2904/4885RAPGEF4 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.